Literature DB >> 15829164

Effect of melatonin on cerebral vasospasm following experimental subarachnoid hemorrhage.

M Volkan Aydin1, Hakan Caner, Orhan Sen, Ozlem Ozen, Basar Atalay, Melih Cekinmez, Nur Altinors.   

Abstract

OBJECT: The current study was undertaken to determine whether melatonin therapy reverses vasospasm and prevents apoptosis by inhibiting lipid peroxidation in an experimental subarachnoid hemorrhage (SAH) model.
MATERIALS AND METHODS: The rabbits were divided into four groups as follows: Group 1, SAH + melatonin (5 mg/kg/i.p. BID) simultaneously with SAH (n = 6); Group 2, SAH + melatonin (5 mg/kg/i.p. BID) treated 2 hours after SAH (n = 6); Group 3, control group (n = 4); Group 4, SAH only (n = 6). Light microscopic examinations of the basilar arteries were performed to demonstrate the pathophysiological changes of the arterial wall with hematoxylin- eosin. Apoptosis: Immunohistology using the ApopTag Peroxidase In Situ Apoptosis Detection Kit was used to demonstrate apoptosis in a cross section of basilary arteries. Apoptotic index was calculated as the number of the immunoreactive nuclei per total number of endothelial cells, and expressed as a percentage.
RESULTS: The results of measurements of diameters of the vessels between groups were significantly different (p = 0.028). While basilar arteries of the SAH only group showed 57% constriction, Groups 1 and 2 were calculated as 33 and 26% constriction, respectively, compared with the control group (p < 0.05). And also Groups 1 and 2 showed significant protection of apoptosis compared with Group 4. The difference between the four groups was tested by Kruskal-Wallis test and the significance between the two groups was tested by Mann- Whitney U-test.
CONCLUSION: Melatonin with its strong antioxidant effect can prevent SAH-induced vasospasm and apoptosis of endothelial cells of vessels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15829164     DOI: 10.1179/016164105X18331

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  7 in total

Review 1.  Neuroprotective Mechanisms of Melatonin in Hemorrhagic Stroke.

Authors:  Hai-Jian Wu; Cheng Wu; Huan-Jiang Niu; Kun Wang; Lian-Jie Mo; An-Wen Shao; Brandon J Dixon; Jian-Min Zhang; Shu-Xu Yang; Yi-Rong Wang
Journal:  Cell Mol Neurobiol       Date:  2017-01-28       Impact factor: 5.046

Review 2.  The single and double blood injection rabbit subarachnoid hemorrhage model.

Authors:  Yuichiro Kikkawa; Ryota Kurogi; Tomio Sasaki
Journal:  Transl Stroke Res       Date:  2014-11-08       Impact factor: 6.829

Review 3.  Melatonin as a Potential Neuroprotectant: Mechanisms in Subarachnoid Hemorrhage-Induced Early Brain Injury.

Authors:  Chengyan Xu; Zixia He; Jiabin Li
Journal:  Front Aging Neurosci       Date:  2022-04-29       Impact factor: 5.702

4.  Influence of melatonin on cerebrovascular proinflammatory mediators expression and oxidative stress following subarachnoid hemorrhage in rabbits.

Authors:  Qi Fang; Gang Chen; Weiwei Zhu; Wanli Dong; Zhong Wang
Journal:  Mediators Inflamm       Date:  2010-01-31       Impact factor: 4.711

5.  Long non-coding RNA and microRNA-675/let-7a mediates the protective effect of melatonin against early brain injury after subarachnoid hemorrhage via targeting TP53 and neural growth factor.

Authors:  Song Yang; Wanzhong Tang; Yuchao He; Linbao Wen; Bin Sun; Shengli Li
Journal:  Cell Death Dis       Date:  2018-01-24       Impact factor: 8.469

Review 6.  Neuroprotective Role of the Nrf2 Pathway in Subarachnoid Haemorrhage and Its Therapeutic Potential.

Authors:  Ardalan Zolnourian; Ian Galea; Diederik Bulters
Journal:  Oxid Med Cell Longev       Date:  2019-05-02       Impact factor: 6.543

7.  MEL Ameliorates Post-SAH Cerebral Vasospasm by Affecting the Expression of eNOS and HIF1α via H19/miR-138/eNOS/NO and H19/miR-675/HIF1α.

Authors:  Guoqiang Hou; Hongjin Chen; Yuhua Yin; Yaohua Pan; Xiaohua Zhang; Feng Jia
Journal:  Mol Ther Nucleic Acids       Date:  2019-12-14       Impact factor: 8.886

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.